|
pubmed:abstractText |
Onercept is a recombinant human soluble p55 tumor necrosis factor binding protein under development by Serono for the potential treatment of a number of disorders, including Crohn's disease, psoriasis and psoriatic arthritis. In March 2002, phase II trials were ongoing for these indications, and in February 2003, Serono expected phase III trials in psoriatic arthritis to commence in the second half of 2003.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Rheumatology, Medical School, University of Ioannina, Ioannina 45110, Greece. snnikas@yahoo.com
|
